贝伐珠单抗联合长春瑞滨二线治疗复发转移性宫颈癌患者的近期疗效

目的:观察贝伐珠单抗联合长春瑞滨治疗复发转移性宫颈癌的近期疗效及不良反应。方法:回顾性分析2014年1月至2016年12月贵州省人民医院收治的34例复发转移性宫颈癌患者的临床资料，所有患者均使用贝伐珠单抗联合长春瑞滨，21天为1个周期，行4～6个周期治疗，评价疗效及评定不良反应级别。结果:34例宫颈癌患者中无完全缓解患者，部分缓解7例（20.6%）、疾病稳定20例（58.8%）、疾病进展7例(20.6%），总有效率为 20.6%（7/34），疾病控制率为79.4%（27/34）。34例患者常见不良反应程度均较轻，可以耐受。结论:贝伐珠单抗联合长春瑞滨方案治疗复发转移性宫颈癌患者近期疗效好，其不良反应患者可耐受，远期疗效有待进一步的研究。

Short-term efficacy of bevacizumab combined with vinorelbine in the treatment of patients with recurrent metastatic cervical cancer as second-line drugs

Objective:To observe the short-term efficacy and side effects of bevacizumab combined with vinorelbine in recurrent and metastatic cervical cancer patients.Methods:The clinical data of 34 patients with recurrent metastatic cervical cancer that were admitted to the Department of Oncology，Guizhou Provincial People's Hospital from January 2014 to December 2016，were retrospectively analyzed.All patients were treated with bevacizumab plus vinorelbine.In the 21-day cycle，chemotherapy was applied for 4 to 6 cycles.The efficacy and level of side effects were evaluated.Results:In the 34 patients with cervical cancer，0 had complete remission (CR)，7(20.6%) had partial remission (PR)，20(58.8%) had stable disease (SD)，and 7(20.6%) had disease progression（PD）.The effective rate (RR) was 20.6%(7/34) and the disease control rate(DCR) was 79.4%(27/34).34 patients with common adverse reactions of lesser extent can be tolerated.Conclusion:Bevacizumab combined with vinorelbine has a good short-term effect in patients with recurrent and metastatic cervical cancer，and its side-effect can be tolerated.Further studies are needed to evaluate the long-term efficacy and side effects of bevacizumab and viorelbine in recurrent and metastatic cervical cancer patients.